Sa1094 Developing Benchmarks for Clinically Meaningful Change for IBS-C Symptoms Using Data From Two Phase 3 Trials of Linaclotide
Brennan Spiegel(Cedars-Sinai Medical Center), Jeffrey M. Johnston(Ironwood Pharmaceuticals (United States)), Valerie Williams(RTI International), Harvey Schneier, Lauren Nelson(RTI Health Solutions), Caroline B. Kurtz(Ironwood Pharmaceuticals (United States)), Xinwei D. Jia, Mark G. Currie(Flinders University), James E. MacDougall(BioBridges (United States)), Giles R. Locke, Robyn T. Carson(Forest Research Institute)
Cited by 2
Related Papers
Selective inhibition of the inducible nitric oxide synthase by aminoguanidine
|European Journal of Pharmacology|1993|727
Development and Validation of the Rome IV Diagnostic Questionnaire for Adults
|Gastroenterology|2016|696
Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate‐to‐severe atopic dermatitis
|British Journal of Dermatology|2019|384